Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone.
The Company's lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer is currently undergoing a multi-center Phase IIb clinical trial in Italy. This is the first of three carefully planned proof-of-concept clinical trials to establish the superiority of combinatorial immunotherapy either with front-line chemotherapy consisting of carboplatin/paclitaxel in ovarian cancer, gemcitabine in pancreatic cancer, or with the addition of an immunoadjuvant. The Company hopes that successful results from these studies will lead to the design of a definitive product registration study.
Sep 16, 2014
Quest PharmaTech Provides Financial Update
Jun 9, 2014
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer
Jan 29, 2014
Quest PharmaTech Announces Third Combinatorial Immunotherapy Clinical Trial for Oregovomab with a TLR3 agonist, HiltonolÂ®
Nov 21, 2013
Quest PharmaTech Announces $1,000,000 Non-Brokered Private Placement
Nov 07, 2013
Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to present late-breaking data at the 28th Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8 - 10, 2013 in Maryland, U.S.
Jul 23, 2013
Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer
Apr 08, 2013
Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti - PSA IgE preclinical data at the 2013 American Association for Cancer Research Conference
Jan 22, 2013
Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.
To Be Announced